Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. [2]

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.

Explore Regeneron’s clinical pipeline. Our pipeline is powered by end-to-end research and development capabilities, and our portfolio of investigational medicines reflects the true collaborative spirit of Regeneron. The Research team discovers promising new drug candidates.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Learn more about Regeneron Download our corporate fact sheet

Search for a Regeneron clinical trial based on condition, keyword, and location. Explore comprehensive information on our highlighted trials to learn more.

Regeneron collaborates with Truveta and leading American health systems to massively extend its DNA sequence-linked healthcare database to further advance scientific innovation and healthcare delivery

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

Explore how Regeneron advanced its mission in 2022 by developing medicines to address serious diseases across several therapeutic areas.

Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, nationality, national or ethnic origin, civil status, age, citizenship status, membership of the Traveler community, sexual orientation, disability, genetic ...